Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic hepatitis delta: phase 3 D-LIVR trial

HomePublication & PresentationsHistologic improvement and reduction in...

About Us

We focus on infectious diseases with high unmet needs because we believe no patients should be left behind.
About EIT Pharma

Pipeline

Our lead assets are being developed as treatments for Hepatitis D and Acute Respiratory Infection (ARI).
Pipeline

Contact Us

Email: info@eitpharma.com11335 NE 122nd Way - Suite 105Kirkland, WA 98034-6933
Get Directions

Copyright © 2026 EIT Pharma, Inc. All rights reserved.